The AKR7A3 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population derived from the human A-549 lung adenocarcinoma epithelial line, featuring targeted disruption of the AKR7A3 gene. This knockout model is designed to eliminate functional AKR7A3 protein expression, and the polyclonal nature provides a heterogeneous population of edited alleles, suitable for studying gene function without the clonal selection pressure inherent in single-cell-derived lines. The disruption is achieved through CRISPR/Cas9-mediated genome editing, generating a loss-of-function model that enables investigation of AKR7A3-dependent processes in a human lung epithelial context.
The host cell line A-549 is a widely utilized model of human alveolar type II pulmonary epithelium, originally established from a 58-year-old Caucasian male with lung adenocarcinoma. These adherent epithelial cells exhibit typical characteristics of transformed lung tissue and are extensively applied in cancer biology, drug metabolism, and toxicology studies. Their relevance to pulmonary carcinogenesis and oxidative stress responses makes them an appropriate platform for dissecting the roles of detoxification enzymes like AKR7A3.
AKR7A3 encodes an NADPH-dependent aldo-keto reductase that reduces cytotoxic aldehydes and ketones, including aflatoxin B1 aldehyde, to less toxic alcohols. This activity limits protein carbonylation and DNA adduct formation, mitigating oxidative and electrophilic stress. Transcription of AKR7A3 is activated by NRF2, which, under oxidative stress, dissociates from KEAP1, translocates to the nucleus, and binds ARE sequences together with small MAF proteins. The enzyme interacts physically with NADPH and functionally with other aldo-keto reductase members and glutathione S-transferases (GSTs). Loss of AKR7A3 disrupts this detoxification cascade, causing accumulation of reactive carbonyls, elevated DNA damage, and increased susceptibility to oxidative stress-induced apoptosis or malignant transformation.
In the A-549 cellular background, loss of AKR7A3 has profound implications for redox homeostasis and genotoxic defense. Given the lung’s exposure to inhaled xenobiotics and endogenous oxidative byproducts, AKR7A3 serves as a frontline protector. Its knockout in this model sensitizes cells to aflatoxin B1 cytotoxicity and oxidative challenges, recapitulating vulnerabilities that may underlie chemoresistance or carcinogenic progression in lung tissue. This system allows researchers to dissect how AKR7A3-mediated metabolism influences NRF2 pathway dynamics, glutathione conjugation, and downstream stress signaling in an epithelial malignancy context.
This polyclonal knockout cell population is a versatile tool for investigating aflatoxin B1 detoxification mechanisms, oxidative stress response pathways, and the role of AKR7A3 in lung cancer chemoresistance. It is well-suited for NRF2/KEAP1 pathway research, carcinogenesis and DNA damage assays, and drug metabolism studies. Representative assays include Western blotting, RT-qPCR, ROS measurement, MTT viability, apoptosis assays, aflatoxin B1 cytotoxicity, DNA adduct detection, and aldo-keto reductase activity assays, as well as NRF2 reporter assays. For further details, please contact Ascent Research.
